Autres langues Coeptis Therapeutics Holdings, Inc.

Actions

COEP

US19207A1088

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 20/05/2024			Varia. 5j.	Varia. 1 janv.
0,3326 ^USD	-5,00%		-6,60%	-57,57%

10/05	Coeptis Therapeutics Holdings, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
26/03	Coeptis Therapeutics Holdings, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024	08/05
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene and Cell Therapy 27th Annual Meeting	03/05
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	03/04
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	02/04
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	27/02
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	26/02
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	07/02
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	04/01
Coeptis Therapeutics to Present at the Emerging Growth Conference	04/12
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding	03/11
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	31/10/23
Coeptis Therapeutics Announces $2 Million Private Placement	24/10/23
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding	24/10/23
Coeptis Therapeutics : Private Placement - Form 8-K	13/10/23
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	11/10/23
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	11/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Coeptis Therapeutics Holdings, Inc.

Actions

COEP

US19207A1088

Autres langues

Filtres